Visiomed Group

Following the merger of Visiomed Group Limited and Clinical Cell Culture (C3) the newly formed corporate entity is now Avita Medical Limited (ASX: AVH). 

The company a publicly listed biomedical company that is evolving to become a global medical device company and active in the regenerative medicine and respiratory markets.

Respiratory                                                       

The Company commercialises innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases.  We also manufacture and sell a range of spacers for the paediatric, adolescent and adult market and is the leading provider of spacers in Australia.

The Funhaler® incentive asthma spacer has been designed specifically for the paediatric market, incorporating auditory and visual incentives to encourage children to comply with their medication plan.  Clinically demonstrated to improve compliance to prescribed medication by 38% and increase proper inhalation technique in children by 60%.  The Funhaler® is patented, CE marked for the EU, FDA cleared for the USA and included on the Australian Register of Therapeutic Goods.

Breath-A-Tech is the leading spacer for adolescents and adults in Australia.  The product is effective, compact, easy to use and competitively priced.  The Breath-A-Tech hospital-grade spacer can also be autoclaved in the hospital or clinical setting.

Regenerative Medicine

The Company develops and distributes tissue-engineered products for the treatment of wounds and other skin defects.  Using proprietary tissue-culture/collection technology, the company is able to provide innovate treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

ReCell® is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells that are collected during surgery.  ReCell® has been designed for use in a wide variety of plastic, reconstructive and cosmetic procedures.  ReCell®  is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.

ReCell®  is approved for sale in Australia, Brazil, Canada, Chile, Croatia, European Union, Hong Kong, Isreal, Japan, Malaysia, New Zealand, Norway, Singapore, South Africa, Switzerland and Turkey.  The company is currently focussed on securing FDA approval fo rsale of the product in the USA.